Interferon beta-1b biosimilar (InSight Biopharmaceuticals)

干扰素β-1b生物类似药 (InSight Biopharmaceuticals)

Report date: 2022/02/21 13:59:37

Base Information

Drug NameInterferon beta-1b biosimilar (InSight Biopharmaceuticals)
Drug Alias Name干扰素β-1b生物仿制药 (InSight Biopharmaceuticals)
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsMultiple Sclerosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved Date2015/01/01
Country/TerritoryN/A
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesInsight Biopharmaceuticals
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeL03AB08
Related LinksN/A